Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

f Ambit's drug development programs, including the submission of regulatory filings and planned discussions with regulatory bodies, plans regarding future clinical trials of quizartinib and Ambit's other drug candidates, the progress and expected timing of clinical trials, the presentation of data from clinical trials, the clinical benefits to be derived from quizartinib and Ambit's other drug candidates, the regulatory approval path for quizartinib, the strength of Ambit's balance sheet and adequacy of cash on hand, and Ambit's financial guidance.. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as  "plans," "expects," "anticipates," "hopes", "may," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

  Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Statements of Operations(unaudited, in thou
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Nektar Therapeutics (NASDAQ: NKTR ... the analgesic profiles of a series of the ... molecules. The preclinical research candidates were created using ... The analgesic properties of kappa receptor agonism ... Kappa opioid receptors are expressed in the ...
(Date:9/19/2014)... Florida , September 19, 2014 ... release latest developments, patents and results of studies and ... Eli Lilly and Company (NYSE: LLY ), ... Corporation (NASDAQ: CELG ) and Arena Pharmaceuticals ... a leader in developing prodrug therapeutics for the treatment ...
(Date:9/19/2014)... Minnesota (PRWEB) September 19, 2014 ... related food industries will gather October 5–8, 2014, ... the Rhode Island Convention Center in Providence, Rhode ... feature the work of food scientists, chemists, microbiologists, ... control, and food production management. To date, 1,000 ...
(Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... , RESEARCH TRIANGLE PARK, N.C. , Feb. 4 ... company developing orally available antiviral therapeutics, announced today that ... as Chief Medical Officer.   , Dr. Painter has more ... work in clinical development, clinical safety and pharmacovigilance, and occupational ...
... ... at India World CEO Forum , ... New Delhi (Vocus) -- Industry has a unique opportunity today to engage, innovate and ... P. Vergnano at the World CEO Forum of the Delhi Sustainable Development Summit ...
... RICHMOND, Calif. , Feb. 3 Sangamo BioSciences, Inc. (Nasdaq: ... and accomplishments and provided an outlook for 2010. , For the fourth ... of $2.4 million , or $0.05 per share, compared to ... share, for the same period in 2008. As of December 31, 2009 ...
Cached Biology Technology:Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 2Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 3Sustainability Is A Business Imperative 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 10Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 11Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 12Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 13
(Date:9/19/2014)... Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ... growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ad ... light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... Katey Sagal have been cast in Bleed for ...
(Date:9/18/2014)... moon of Uranus, is one of the most visually ... its relatively small size, Miranda appears to have experienced ... formation of at least three remarkable and unique surface ... coronae are visible in Miranda,s southern hemisphere, and each ... the largest, has ridges and troughs with up to ...
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... the scientific journal Zootaxa , researchers from Madagascar and ... The new bird was named Mentocrex beankaensis , ... and the new species beankaensis being coined after ... This species was distinguished from another in the same genus, ...
... by Edward Yu of Iowa State University and the Ames Laboratory ... pumps toxins from bacteria and allows them to resist antibiotics. ... journal Nature . The paper describes the co-crystal structure ... removes heavy metal toxins from bacteria. A research team led by ...
... compounds during the last year in search of potential new ... that one substance shows unusual promise. The early positive signs ... and cell cultures, they say in a report in ACS, ... colleagues, who include Nobel Laureate Stanley B. Prusiner, explain that ...
Cached Biology News:New bird to science emphasizes the critical need to conserve the remaining dry forests of Madagascar 2Iowa State, Ames Lab researchers describe the pump that bacteria use to resist drugs 2
... UltraClean GelSpin Kit utilizes a silica based spin ... After electrophoresis, the desired DNA band is cut ... the spin filter unit. The gel slice is ... Then the DNA is bound to the silica ...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
Biology Products: